Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario

Table 1 Baseline demographics and clinical characteristics

Characteristics	n = 77
Age (mean ± SD), yr	55 ± 11.8
Men, n (%)	59 (76.6)
Medical history, n (%)
Hypertension	37 (48.1)
Diabetes	15 (19.48)
Smoking	24 (31.2)
Consumption of alcohol	9 (11.7)
Stroke	2 (2.6)
Previous coronary intervention	4 (5.2)
Previous myocardial infarction	34 (44.2)
Cardiac status, n (%)
Stable angina	30 (39)
Unstable angina	13 (16.9)
STEMI	26 (33.8)
NSTEMI	8 (10.4)
Coronary angiogram finding, n (%)
Single-vessel disease	61 (79.2)
Double-vessel disease	16 (20.8)
Triple-vessel disease	0 (0.0)
Heart rate (mean ± SD), bpm	81.26 ± 12.08
Systolic blood pressure (mean ± SD), mmHg	134.91 ± 27.51
Diastolic blood pressure (mean ± SD), mmHg	83.19 ± 13.57
Serum creatinine (mean ± SD), mg/dL	1.13 ± 0.23
LVEF (mean ± SD), %	46.38 ± 8.19

LVEF: Left ventricular ejection fraction; NSTEMI: Non-stent thrombosis segment elevation myocardial infarction; SD: Standard deviation; STEMI: Stent thrombosis segment elevation myocardial infarction; bpm: Beats per minute.

Table 2 Procedural and lesion characteristics

Characteristics	n = 77
Access site approach, n (%)
Femoral	20 (26)
Radial	57 (74)
Total number of lesions	102
Total number of lesions treated with EverProTM	98
Lesions per patient	1.32
Stents per patient	1.27
Lesion location, n (%)
Right carotid artery	29 (29.6)
Left anterior descending artery	48 (49)
Left circumflex artery	12 (12.2)
Obtuse marginal artery	9 (9.2)
Stenosis type, n (%)
De novo	95 (96.9)
In-stent	3 (3.1)
Thrombus load, n (%)
None	76 (77.6)
Mild	10 (10.2)
Moderate	5 (5.1)
Severe	7 (7.1)
ACC/AHA lesion type, n (%)
A	5 (5.1)
B1	30 (30.6)
B2	38 (38.8)
C	25 (25.5)
Percent stenosis (mean ± SD)	88.39 ± 9.30
Stent length (mean ± SD), mm	18.20 ± 4.34
Stent diameter (mean ± SD), mm	2.89 ± 0.36
TIMI flow post-procedure, n (%)
TIMI 3	98 (100)
Discharge medications, n (%)
Aspirin	77 (100)
Clopidogrel	44 (57.1)
Ticlopidine	2 (2.6)
Prasugrel	3 (3.9)
Ticagrelor	27 (35.1)

ACC: American College of Cardiology; AHA: American Heart Association; SD: Standard deviation; TIMI: Thrombolysis in myocardial infarction.